. [82] to assess the efficacy, protection and tolerability of Cannabidiol as an adjunct therapy in addition to anti-epileptic medicine within the sufferers suffering from tuberous sclerosis advanced whose most typical neurological symptom is epilepsy. With this scientific trial examine, right af